Abstract
Introduction
Three new partnerships are reshaping the competitive environment in HIV. Most
notably, Tibotec/Johnson & Johnson is linking up with Gilead to combine their
Phase III drug rilpivirine with Truvada to create a new gold standard fixed
dose combination for treatment-naive patients. Addressing Atripla' s
shortcomings, Datamonitor expects this product to dominate the market.
Scope of this research
- In-depth analysis of Phase II and III clinical development compounds and
comprehensive overview of Phase I drugs
- An overview of the key companies involved in the HIV pipeline, including
an analysis of the new corporate alliances
- The epidemiology dynamics of HIV in the six major markets are discussed
along with unmet needs that have evolved from the prolonged use of HAART
- Sales forecasts over the next 10 years for the each of the late-stage drugs
Research and analysis highlights
Advances in antiretroviral therapy have addressed the two big unmet medical
needs, resistance and safety. Convenience is the new frontier, pointing
towards a bright future for cross-class fixed-dose combination, notably
Gilead' s Quad Pill and Gilead' s and Johnson & Johnson' s Truvada/rilpivirine
combination.
Gilead' s two new cross-class fixed dose combinations offer only moderate
medical progress, but their added convenience compared with single ingredient
formulations will cement the company' s market leadership and reduce the market
opportunity for single-ingredient formulations.
Abbott' s monopoly in protease inhibitor boosting agents is nearing its end. At
least three companies have pharmacokinetic enhancers with potentially improved
safety profiles in clinical development, hopefully enabling the creation of
more co-formulated brands
Key reasons to purchase this research
- Understand the constantly evolving market dynamics of antiretroviral drugs
in view of corporate alliances, co-formulations and generic entry
- Learn about the changing unmet needs of patients and the extent to which
pipeline drugs are addressing these issues
- Evaluate the forecast of key pipeline antiretroviral drugs to 2018, taking
into account key launch dates, patent expirations and other factors
| 
View Cart
